Press Releases

• November 10, 2022

IconOVir Announces New Preclinical Data Showcasing Best-in-Class Potential of ICVB-1042, its Lead Oncolytic Virus, at SITC 2022

• October 10, 2022

IconOVir Bio Appoints Julia Maltzman, M.D., as Chief Medical Officer

• October 5, 2022

IconOVir Bio to Present Preclinical Data on Lead Candidate ICVB-1042 at SITC 2022

• September 14, 2022

IconOVir Bio to Present at UBS Biotechnology Virtual Private Company Symposium

• June 23, 2022

IconOVir Bio Appoints William Kaelin, Jr., M.D., to Board of Directors

• June 6, 2022

IconOVir Bio Appoints John Huynh, Ph.D., as Chief Technology Officer

• June 3, 2022

IconOVir Bio to Present at Jefferies Healthcare Conference

• May 18, 2022

IconOVir Bio to Present at UBS Global Healthcare Conference

• May 27, 2021

IconOVir Bio to Present at Jefferies Healthcare Conference

• May 20, 2021

IconOVir Bio Announces Preclinical Proof-of-Concept Data for Proprietary Mutations Designed to Improve Selectivity of Novel Oncolytic Viruses, Including Lead Product Candidate ICVB-1042